Clinical Study of SYS6055 Injection in Participants With Relapsed/Refractory Aggressive B-Cell Lymphoma

Inclusion Criteria: * 1\. Age ≥ 18 year, and voluntarily signed the Informed Consent Form (ICF); * 2\. Histologically confirmed aggressive B-cell lymphoma (defined according to the 5th edition of the WHO classification); * 3\. Patients with relapsed/refractory aggressive B-cell lymphoma who failed standard therapy, with CD19-positive tumor cells; * 4\. At least one measurable lesion according to the 2014 Lugano Response Criteria for Lymphoma; * 5\. ECOG performance status score of 0-1; * 6\. Expected survival of at least 3 months; * 7\. Adequate organ and bone marrow function; * 8\. Eligible participants (males and females) of reproductive potential must agree to use a reliable method of contraception (hormonal contraception, barrier method, or abstinence) with their partner during the trial and for at least 1 year after dosing. Female participants of childbearing potential must have a negative serum pregnancy test within 7 days prior to enrollment. In addition, female participants must agree not to donate oocytes (eggs, ova) for assisted reproductive technology for 1 year after dosing, and male participants must agree not to donate sperm for assisted reproductive technology for 1 year after dosing; * 9\. Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures. Exclusion Criteria: * 1\. History of other malignancy within 3 years or concurrent other active malignancy (participants with cured localized tumors such as bas…